

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**THE EFFECT OF PROBIOTICS ON HOST MUCOSAL IMMUNE RESPONSES**

**A thesis presented in partial fulfilment  
of the requirements for the degree of  
Master of Science in Nutritional Science  
at Massey University,  
Palmerston North, New Zealand**

**MEI CHING WONG**

**1998**

## Abstract

Lactic acid bacteria (LAB) are a group of Gram-positive anaerobic bacteria that convert carbohydrates and complex sugars into lactic acid as the end product through fermentation. Several species of LAB have been used as probiotics. Probiotics are mono- or mixed cultures of live microorganisms which, when orally administered to animals or man, benefit them by improving the balance of the indigenous microflora. Lactic acid bacteria are claimed to have several beneficial effects; one of them being stimulation of the immune system. Many studies have demonstrated the immunostimulatory effects of LAB and various mechanisms have been suggested as to how LAB stimulate the immune system. These include the ability of LAB to translocate to Peyer's Patches (PP) and other gut-associated lymphoid tissues (GALT) for immunological processing by immunocompetent cells and production of cytokines. There were three aims in our present studies. The first was to determine the effect of dose of an immunoenhancing probiotic strain *L. rhamnosus* on the mucosal and serum immune responses of mice to oral antigens cholera toxin (CT) and ovalbumin (OV). The second aim was to examine the effect of viability of *L. rhamnosus* on these responses. Various mucosal immune parameters were measured in these studies. Results indicate that the immunostimulatory effects of *L. rhamnosus* were dose-dependent and that the  $1 \times 10^9$  cfu dose was the most appropriate dose for *L. rhamnosus* for its immunostimulatory effects. Viability also affects the immunostimulatory effects of *L. rhamnosus* as shown by the higher efficacy of viable *L. rhamnosus* than non-viable *L. rhamnosus* in stimulation of several aspects of the mucosal immune system. In some other immune parameters, non-viable *L. rhamnosus* was found to be the same as, or more effective than the viable bacteria. These findings were significant in that they provide additional evidence of the dose- and viability-dependency of different LAB. This information will help those involved in the development of probiotic products to consider these factors when formulating their products so that the concentration of live LAB can be adjusted to ensure the product can convey the maximum beneficial effect to the consumer.

The third aim of our studies was to examine the role played by the immune system in protecting against enteric infection. It was found that *L. rhamnosus* increased the resistance of mice to *S. typhimurium* infection as demonstrated by the lower numbers of bacteria found in the liver and spleen, and a maintenance of liveweight. This was also accompanied by increased mucosal and systemic immune responses to *S. typhimurium*. This result suggests that the immune system may play an important role in mediating the protection against enteric infection. Various other mechanisms have also been postulated by which LAB protect against enteric infection, for example, production of antibacterial substances, competition for adherence to the gut wall and for nutrients. However, the precise role and relative importance of these mechanisms in mediating protection against enteric infection is unknown.

This thesis is dedicated to God to whom I owe my life and without whom I would not be able to give my best effort in completing it. Let all glory be unto Him.

## **Acknowledgements**

I am grateful to the Ministry of Foreign Affairs and Trade of New Zealand for granting me a scholarship to pursue a MSc degree in Nutritional Science and also to the Milk and Health Research Centre for granting me a scholarship to conduct my studies.

My sincere thanks and appreciation to my supervisors, Drs H.S.Gill and K.J.Rutherford, for their advice, encouragement and help throughout the course of this study and their patience in teaching me the things that are new to me.

My thanks and appreciation also go to the technicians of the Milk and Health Research Centre, Ms A.Broomfield, Ms S.Blackburn, Ms K.Kennedy, Ms L.Trezise and Mr D.Johnson for their patience in teaching me how to perform various techniques in the laboratory, and for helping me care for the mice and helping me perform some of the assays.

Thanks also to Research Scientist, Dr Q.Shu for his help in performing the SAS analysis of my data, and Mrs J.Richards for helping me solve word processing problems.

Finally, thanks to my family in Malaysia for their encouragement and financial support throughout the course of this study, and my friends who encouraged and prayed for me.

## TABLE OF CONTENTS

		Page
Abstract		ii
Dedication		iv
Acknowledgements		v
Table of Contents		vi
List of Tables		xii
List of Figures		xiv
List of Abbreviations		xvi
Chapter 1	Introduction	1
1.1	Overview of the Immune System	1
1.1.1	Non-Specific Immune System	1
1.1.2	Specific Immune System	2
1.1.2.1	General Properties of Specific Immune Responses	2
1.1.2.2	Phases of the Specific Immune Response	4
1.1.2.3	Cells of the Specific Immune System	5
1.1.3	Tissues of the Immune System	6
1.1.4	The Mechanisms by which the Specific and Non-Specific Immune System Eliminate Antigens	6
1.1.4.1	Mechanisms of Elimination of Antigens by the Non-Specific Immune System	8
1.1.4.2	Mechanisms of Elimination of Antigens by the Specific Immune System	9
1.1.5	Systemic and Mucosal Immune Responses	12
1.1.5.1	Differences Between Systemic and Mucosal Immune Responses	12
1.1.5.2	The Mucosal Immune System	13
1.2	Probiotics	15

1.2.1	Definition	15
1.2.2	Probiotic Bacteria	15
1.2.3	Characteristics of an Effective Probiotic	16
1.2.4	Beneficial Effects of Probiotic Bacteria	16
	1.2.4.1 Prevention of Bacterial Infection	17
	1.2.4.2 Alleviation of Lactose Intolerance	18
	1.2.4.3 Reduction of Serum Cholesterol Levels	18
	1.2.4.4 Anticarcinogenic Effects	20
	1.2.4.5 Improvement in the Nutritional Value and Quality of Food	22
	1.2.4.6 Other Health Benefits of LAB	22
1.2.5	Effect of LAB on the Immune System	23
	1.2.5.1 Effect of LAB on the Non-Specific Immune System	23
	1.2.5.2 Effect of LAB on the Specific Immune System	24
1.3	Summary	27
1.4	Aims of the Research	27
Chapter 2	Materials and Methods	28
2.1	Materials and Methods I	28
	2.1.1 Animals	28
	2.1.2 Probiotic Bacteria	28
	2.1.3 Oral Antigens	28
	2.1.4 Preparation of Lymphocytes from Mesenteric Lymph Nodes	28
	2.1.5 Preparation of Lymphocytes from Peyer's Patches	29
	2.1.6 Preparation of Serum	30



2.1.7	Preparation of Intestinal Contents	30
2.1.8	The Cell Proliferation Assay	30
2.1.9	The Immunophenotyping Assay	31
2.1.10	The Enzyme-Linked Immunosorbent Assay (ELISA)	32
2.1.11	The <i>In Vitro</i> Antibody Assay	33
2.1.12	Statistical Analysis of Results	33
2.2	Materials and Methods II	33
2.2.1	Animals	33
2.2.2	Probiotic Bacteria	34
2.2.3	Oral Antigens	34
2.2.4	Preparation of Lymphocytes from Mesenteric Lymph Nodes	34
2.2.5	Preparation of Lymphocytes from Peyer's Patches	34
2.2.6	Preparation of Serum	34
2.2.7	Preparation of Intestinal Contents	34
2.2.8	The Cell Proliferation Assay	34
2.2.9	The Immunophenotyping Assay	35
2.2.10	The Enzyme-Linked Immunosorbent Assay	35
2.2.11	The <i>In Vitro</i> Antibody Assay	35
2.2.12	Statistical Analysis of Results	35
2.3	Materials and Methods III	35
2.3.1	Animals	35
2.3.2	Probiotic Bacteria	35
2.3.3	Infection with <i>S. typhimurium</i>	35
2.3.4	Preparation of Lymphocytes from Mesenteric Lymph Nodes	36
2.3.5	Preparation of Lymphocytes from Peyer's Patches	36
2.3.6	The Immunophenotyping Assay	36
2.3.7	The <i>In Vitro</i> Antibody Assay	37
2.3.8	Bacterial Translocation Assay	37
2.3.9	Preparation of Peritoneal Macrophages	37
2.3.10	Phagocytosis by Peripheral Blood Leukocytes	38

2.3.11	Phagocytosis by Peritoneal Macrophages	38
2.3.12	Statistical Analysis of Results	38
Chapter 3		39
3.1	Introduction	39
3.2	Experimental Design	40
3.3	Results	41
3.3.1	Mucosal and Serum Antibody Responses to CT and OV	41
3.3.2	<i>In Vitro</i> Antibody Production	43
3.3.2.1	<i>In Vitro</i> Antibody Production by PP Lymphocytes in Response to CT and OV	43
3.3.2.2	<i>In Vitro</i> Antibody Production by MLN Lymphocytes in Response to CT and OV	44
3.3.3	Expression of Lymphocyte Surface Markers	45
3.3.3.1	Expression of Surface Markers on PP Lymphocytes	45
3.3.3.2	Expression of Surface Markers on MLN Lymphocytes	47
3.3.4	Cell Proliferative Responses to T and B cell Mitogens	48
3.3.4.1	Cell Proliferative Responses of PP Lymphocytes	48
3.4	Discussion	49
3.5	Summary	53
Chapter 4		54
4.1	Introduction	54
4.2	Experimental Design	56
4.3	Results	57
4.3.1	Mucosal Antibody Responses to CT and OV	57
4.3.2	Serum Antibody Responses to CT and OV	57
4.3.3	<i>In Vitro</i> Antibody Production	59
4.3.3.1	<i>In Vitro</i> Antibody Production by PP Lymphocytes in Response to CT and OV	59

4.3.3.2	<i>In Vitro</i> Antibody Production by MLN Lymphocytes in Response to CT and OV	61
4.3.4	Expression of Lymphocyte Surface Markers	63
4.3.4.1	Expression of Surface Markers on PP Lymphocytes	63
4.3.4.2	Expression of Surface Markers on MLN Lymphocytes	65
4.4	Discussion	67
4.5	Summary	70
Chapter 5		71
5.1	Introduction	71
5.2	Experimental Design	74
5.3	Results	75
5.3.1	Liveweight Change	75
5.3.2	Number of Viable of <i>S. typhimurium</i> in the Liver and Spleen of Mice	76
5.3.3	Effect of Feeding <i>L. rhamnosus</i> on the Phagocytic Activity of Peritoneal Macrophages	76
5.3.4	Effect of Feeding <i>L. rhamnosus</i> on the Phagocytic Activity of Peripheral Blood Leukocytes	77
5.3.5	Effect of Feeding <i>L. rhamnosus</i> on the <i>In Vitro</i> Antibody Production by PP and MLN Lymphocytes in Response to LTA from <i>S. typhimurium</i>	78
5.3.6	Effect of Feeding <i>L. rhamnosus</i> on the Expression of Surface Markers on PP Lymphocytes	81
5.3.7	Effect of Feeding <i>L. rhamnosus</i> on the Expression of Surface Markers on MLN Lymphocytes	83
5.4	Discussion	84
5.5	Summary	88

Chapter 6		
6.1	General Discussion and Conclusions	89
References		95

**LIST OF TABLES**

Table		Page
1	Examples of Microorganisms Used in Probiotic Products	15
2	Feeding and Vaccination Schedule	40
3	Effect of Various <i>L. rhamnosus</i> Doses on the Serum Antibody Responses to CT and OV	41
4	Effect of Various <i>L. rhamnosus</i> Doses on the <i>In Vitro</i> Antibody Production by PP Lymphocytes in Response to CT and OV	43
5	Effect of Various <i>L. rhamnosus</i> Doses on the <i>In Vitro</i> Antibody Production by MLN Lymphocytes in Response to CT and OV	44
6	Effect of Various <i>L. rhamnosus</i> Doses on the Expression of Surface Markers on PP Lymphocytes	45
7	Effect of Various <i>L. rhamnosus</i> Doses on the Expression of Surface Markers on MLN Lymphocytes	47
8	Effect of Various <i>L. rhamnosus</i> Doses on the Cell Proliferative Responses of PP Lymphocytes to LPS and PHA	48
9	Feeding and Vaccination Schedule	56
10	Serum Antibody Responses to CT and OV	57

11	Effect of Live or Dead <i>L. rhamnosus</i> on the <i>In Vitro</i> Antibody Production by PP Lymphocytes in Response to CT	59
12	Effect of Live or Dead <i>L. rhamnosus</i> on the <i>In Vitro</i> Antibody Production by MLN Lymphocytes in Response to CT	61
13	Immunophenotyping of PP Lymphocytes	63
14	Immunophenotyping of MLN Lymphocytes	65
15	Treatment Schedule	74
16	Log Number of Viable <i>S. typhimurium</i> in Liver and Spleen of Mice Challenged with <i>S. typhimurium</i>	76
17	<i>In Vitro</i> IgA and IgG Production by MLN Lymphocytes in Response to LTA	79
18	Immunophenotyping of PP Lymphocytes	81
19	Immunophenotyping of MLN Lymphocytes	83

**LIST OF FIGURES**

Figure		Page
1	Phases of Specific Immune Responses	4
2	Process of Antigen Recognition and Elimination by the Specific and Non-Specific Immune System	7
3	Some Mechanisms of Elimination of Antigens During Non-Specific Immune Responses	9
4	Process of Humoral Immune Responses to Protein Antigens	10
5	Some Mechanisms of Elimination of Antigens During Specific Immune Responses	11
6	Pathway of the Stimulation of the Common Mucosal Immune System	14
7	Mucosal Antibody Response to CT	42
8	Mucosal Antibody Response to OV	42
9	Percentage of CD25 <sup>+</sup> PP Lymphocytes	46
10	Percentage of CD25 <sup>+</sup> MLN Lymphocytes	46
11	Mucosal Antibody Response to CT	58
12	Mucosal Antibody Response to OV	58

13	<i>In Vitro</i> IgA Production by PP Lymphocytes in Response to OV	60
14	<i>In Vitro</i> IgG Production by PP Lymphocytes in Response to OV	60
15	<i>In Vitro</i> IgA Production by MLN Lymphocytes in Response to OV	62
16	<i>In Vitro</i> IgG Production by MLN Lymphocytes in Response to OV	62
17	Percentage of CD25 <sup>+</sup> PP Lymphocytes	64
18	Percentage of CD25 <sup>+</sup> MLN Lymphocytes	66
19	Effect of <i>L. rhamnosus</i> on the Liveweight Change in Mice	75
20	Phagocytic Activity of Peritoneal Macrophages to FITC- <i>E. coli</i>	77
21	Phagocytic Activity of Peripheral Blood Leukocytes to FITC- <i>E. coli</i>	78
22	<i>In Vitro</i> IgA Production by PP Lymphocytes in Response to LTA	80
23	<i>In Vitro</i> IgG Production by PP Lymphocytes in Response to LTA	80
24	Percentage of CD4 <sup>+</sup> PP Lymphocytes	82
25	Diagram Illustrating the Process of Invasion of the PP of Mice by <i>S. typhimurium</i>	87



**List of Abbreviations**

CD	Cluster differentiation
CT	Cholera toxin
IgA	Immunoglobulin A
IgG	Immunoglobulin G
<i>L. rhamnosus</i>	<i>Lactobacillus rhamnosus</i>
LAB	Lactic acid bacteria
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
MLN	Mesenteric lymph nodes
OV	Ovalbumin
PHA	Phytohemagglutinin
PP	Peyer's Patches
<i>S. typhimurium</i>	<i>Salmonella typhimurim</i>